ProteoGenix is founding the new library of antibodies to bolster the development of VHH antibodies.
FREMONT, CA: ProteoGenix has inaugurated a new single domain library of antibodies. This library is framed to specifically accelerate the development of the next generation VHH antibodies. The antibody library aims at adding value to the development of biotherapeutics and diagnostics.
The comapny believes that VHH antibodies make a great replacement for conventional antibodies. VHH has features that favor them for future applications. The characteristic properties of the antibodies, such as the small size, and others, override a lot of operational obstacles. The new library helps the companies to empower and enable the development pipeline of the therapeutics induced by the VHH antibody.
Increased stability, ability to target unaccessible epitopes, faster clearance, efficient tissue penetration, and ease of engineering into versatile multi-specific formats and more have been the reason for VHH antibodies to gain immense traction. All this put together, the VHH antibody library makes an ideal choice for companies and research centers to advance the development of next-generation biotherapeutics and diagnostic tools.
The new antibody library created by ProteoGenix, serves as a platform to gathers the antibody repertoires from more than 50 healthy donors, all across three camelid species, namely alpacas, camels, and llamas.
With a diverse range of the clones being more than 1010, the library also operates at low quantities of antigens to facilitate screening with phage display. With the combination of the clonal diversity and the powerful screening ability of phage display, the discovery of antibodies can be accelerated. This also shoots up the tight and specific antigen-binding properties 3x faster than normal approaches and at low cost as well.
ProteoGenix is one of the leading contract research organizations and highly popular company working towards the discovery of peptide, protein, and antibody. The mission line of the company is to encourage researchers during the early stages of biotherapeutics and diagnostics development, and vaccine design.